Employer-Paid Nonmedical Costs for Patients With Diabetes and End-Stage Renal Disease

por Kamal-Bahl, Sachin J, Pantely, Susan, Pyenson, Bruce, Alexander, Charles M
Publicado 2006

Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes

por Stargardt, Tom, Gonder-Frederick, Linda, Krobot, Karl J, Alexander, Charles M
Publicado 2009

Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes

por Sinclair, Alan J, Alexander, Charles M, Davies, Michael J, Zhao, Changgeng, Mavros, Panagiotis
Publicado 2012

Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes

por Tunceli, Kaan, Zhao, Changgeng, Davies, Michael J, Brodovicz, Kimberly G, Alexander, Charles M, Iglay, Kristy, Radican, Larry
Publicado 2015

Disparities in lipid management for African Americans and Caucasians with coronary artery disease: A national cross-sectional study

por Massing, Mark W, Foley, Kathleen A, Carter-Edwards, Lori, Sueta, Carla A, Alexander, Charles M, Simpson, Ross J
Publicado 2004

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus

por Hauber, A. Brett, Tunceli, Kaan, Yang, Jui-Chen, Gantz, Ira, Brodovicz, Kimberly G., Alexander, Charles M., Davies, Michael J., Radican, Larry
Publicado 2015

Cholesterol Levels and Statin Use in Patients With Coronary Heart Disease Treated in Primary Care Settings

por O’Connor, Patrick J, Gray, Richard J, Maciosek, Michael V, Fillbrandt, Kelly M, DeFor, Terese A, Alexander, Charles M, Weiss, Thomas W, Teutsch, Steven M
Publicado 2005

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

por Hauber, A Brett, Han, Steven, Yang, Jui-Chen, Gantz, Ira, Tunceli, Kaan, Gonzalez, Juan Marcos, Brodovicz, Kimberly, Alexander, Charles M, Davies, Michael, Iglay, Kristy, Zhang, Qiaoyi, Radican, Larry
Publicado 2013

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

por Danne, Thomas, Garg, Satish, Peters, Anne L., Buse, John B., Mathieu, Chantal, Pettus, Jeremy H., Alexander, Charles M., Battelino, Tadej, Ampudia-Blasco, F. Javier, Bode, Bruce W., Cariou, Bertrand, Close, Kelly L., Dandona, Paresh, Dutta, Sanjoy, Ferrannini, Ele, Fourlanos, Spiros, Grunberger, George, Heller, Simon R., Henry, Robert R., Kurian, Martin J., Kushner, Jake A., Oron, Tal, Parkin, Christopher G., Pieber, Thomas R., Rodbard, Helena W., Schatz, Desmond, Skyler, Jay S., Tamborlane, William V., Yokote, Koutaro, Phillip, Moshe
Publicado 2019